High-throughput phenogenotyping of Mycobacteria tuberculosis clinical strains reveals bacterial determinants of treatment outcomes
Sydney Stanley, Caitlin N. Spaulding, Qingyun Liu, Michael R. Chase, Đặng Thị Minh Hà, Phan Vuong Khac Thai, Nguyễn Hữu Lân, Do Dang Anh Thu, Nguyen Le Quang, Jessica Brown, Nathan Hicks, Xin Wang, Maximillian G. Marin, Nicole C. Howard, Andrew J. Vickers, Wiktor M. Karpinski, Michael C. Chao, Maha Farhat, Maxine Caws, Sarah J. Dunstan, Nguyễn Thụy Thương Thương, Sarah M. FortunebioRxiv2023 · DOI
This study introduces a high-throughput phenogenotyping platform for Mycobacterium tuberculosis (Mtb) clinical strains, enabling the discovery of bacterial traits linked to treatment outcomes. They found that a specific lineage of Mtb strains exhibits slow growth under stress conditions, which is associated with cavitary disease, treatment failure, and increased transmission, suggesting a link between bacterial growth regulation and clinical severity.
What Problem Does This Paper Address?
Combating tuberculosis (TB) requires understanding the factors that influence patient outcomes and transmission. While host and environmental factors are well-studied, the role of Mtb's genetic background and phenotypic diversity in clinical outcomes remains underexplored. Previous research has linked Mtb lineages to certain clinical features, but the underlying bacterial mechanisms are largely unknown. This paper aims to bridge this gap by identifying bacterial traits that act as intermediate links between Mtb genetics and clinical outcomes, moving beyond simple drug resistance associations.
Methods
The researchers developed a novel high-throughput functional genomics platform for M. tuberculosis. This platform involves genetically barcoding clinical Mtb strains, allowing them to be pooled and competed against each other in various in vitro conditions. Strain abundance is then tracked using deep sequencing. This approach enables the measurement of "phenotypic fitness profiles" under 14 different host-relevant metabolic and antibiotic stress conditions. These fitness profiles serve as intermediate traits. They then used these traits in a bacterial Genome-Wide Association Study (GWAS) to identify genetic variants associated with specific fitness phenotypes and subsequently linked these to clinical outcomes.
Datasets
The study utilized a dataset of 158 M. tuberculosis clinical strains collected from a population-based study of Mtb transmission in Ho Chi Minh City, Vietnam. These strains were paired with high-level patient data, including age, sex, lung cavitation status (identified via chest radiography), and treatment outcome.
Key Insights and Ideas
Phenogenomics as a Bridge: The core idea is using detailed phenotypic profiles (fitness under stress) as "intermediate traits" to connect bacterial genetics to complex clinical outcomes. This is analogous to how intermediate phenotypes are used in human genetics to dissect complex diseases.
Slow Growth as an Advantage: Counterintuitively, slower growth under stress conditions, observed in a specific Mtb lineage, was linked to worse clinical outcomes. This suggests that in certain contexts, growth arrest might be an adaptive strategy for Mtb, aiding in persistence or evading host defenses.
Lineage-Specific Phenotypes: The study highlights that Mtb strains are not uniform, and specific lineages (like the L1.1.1.1 subclade) exhibit distinct phenotypic profiles that are strongly associated with clinical outcomes. This moves beyond broad lineage associations to finer-grained understanding.
Mechanistic Links: By identifying specific genes and pathways associated with these fitness phenotypes, the study provides potential mechanistic explanations for how bacterial traits influence disease severity and transmission.
Key Results
The developed platform successfully generated fitness profiles for 158 Mtb clinical isolates across 14 metabolic and antibiotic stress conditions.
A specific subclade of Lineage 1 strains (L1.1.1.1) was identified as having a universal slow growth phenotype under most antibiotic and metabolic stress conditions in vitro.
This L1.1.1.1 clade was significantly associated with cavitary disease (44% vs. 24% in other strains) and treatment failure (22% vs. 6% in other strains).
The L1.1.1.1 clade also showed evidence of increased transmission potential, indicated by smaller terminal branch lengths (a proxy for recent transmission).
A monogenic association was found between mutations in Rv1339 (a phosphodiesterase) and slower growth in glycerol, which was further linked to treatment failure.
The study identified clade-defining mutations in the L1.1.1.1 subgroup related to resistance pathways for BDQ and CFZ, suggesting adaptation to host pressures.
Limitations and Future Work
Geographic Specificity: While the L1.1.1.1 clade's phenotypes are pertinent to Vietnam, the study acknowledges that further work is needed to understand the mechanisms driving its biogeographical restriction and potential expansion.
Causality vs. Marker: The identified intermediate phenotypes might be directly causal for the clinical outcomes or serve as markers for underlying, yet unidentified, bacterial determinants.
Generalizability: The study focused on drug-susceptible strains and a specific geographic region. Future work could explore these phenotypes in drug-resistant strains and across diverse global populations.
Mechanistic Elucidation: While the study identifies candidate genes and pathways, further experimental validation is needed to fully elucidate the mechanisms by which these bacterial traits influence clinical outcomes.
Transmission Dynamics: While transmission potential is suggested, more definitive analyses are needed to assess transmission dynamics more thoroughly.
Summary updated
Abstract
Abstract Background Combatting the tuberculosis (TB) epidemic caused by Mycobacterium tuberculosis ( Mtb ) necessitates a better understanding of the factors contributing to patient clinical outcomes and transmission. While host and environmental factors have been evaluated, the impact of Mtb genetic background and phenotypic diversity is underexplored. Previous work has made associations between Mtb genetic lineages and some clinical and epidemiological features, but the bacterial traits underlying these connections are largely unknown. Methods We developed a high-throughput functional genomics platform for defining genotype-phenotype relationships across a panel of Mtb clinical isolates. These phenotypic fitness profiles function as intermediate traits which can be linked to Mtb genetic variants and associated with clinical and epidemiological outcomes. We applied this approach to a collection of 158 Mtb strains from a study of Mtb transmission in Ho Chi Minh City, Vietnam. Mtb strains were genetically tagged in multiplicate, which allowed us to pool the strains and assess in vitro competitive fitness using deep sequencing across a set of 14 host-relevant antibiotic and metabolic conditions. Phylogenetic and monogenic associations with these intermediate traits were identified and then associated with clinical outcomes. Findings Mtb clinical strains have a broad range of growth and drug response dynamics that can be clustered by their phylogenetic relationships. We identified novel monogenic associations with Mtb fitness in various metabolic and antibiotic conditions. Among these, we find that mutations in Rv1339 , a phosphodiesterase, which were identified through their association with slow growth in glycerol, are further associated with treatment failure. We also identify a previously uncharacterized subclade of Lineage 1 strains (L1.1.1.1) that is phenotypically distinguished by slow growth under most antibiotic and metabolic stress conditions in vitro . This clade is associated with cavitary disease, treatment failure, and demonstrates increased transmission potential. Interpretation High-throughput phenogenotyping of Mtb clinical strains enabled bacterial intermediate trait identification that can provide a mechanistic link between Mtb genetic variation and patient clinical outcomes. Mtb strains associated with cavitary disease, treatment failure, and transmission potential display intermediate phenotypes distinguished by slow growth under various antibiotic and metabolic conditions. These data suggest that Mtb growth regulation is an adaptive advantage for host bacterial success in human populations, in at least some circumstances. These data further suggest markers for the underlying bacterial processes that govern these clinical outcomes. Funding National Institutes of Allergy and Infectious Diseases: P01 AI132130 (SS, SMF); P01 AI143575 (XW, SMF); U19 AI142793 (QL, SMF); 5T32AI132120-03 (SS); 5T32AI132120-04 (SS); 5T32AI049928-17 (SS) Wellcome Trust Fellowship in Public Health and Tropical Medicine: 097124/Z/11/Z (NTTT) National Health and Medical Research Council (NHMRC)/A*STAR joint call: APP1056689 (SJD) The funding sources had no involvement in study methodology, data collection, analysis, and interpretation nor in the writing or submission of the manuscript. Research in context Evidence before this study We used different combinations of the words mycobacterium tuberculosis, tuberculosis, clinical strains, intermediate phenotypes, genetic barcoding, phenogenomics, cavitary disease, treatment failure, and transmission to search the PubMed database for all studies published up until January 20 th , 2022. We only considered English language publications, which biases our search. Previous work linking Mtb determinants to clinical or epidemiological data has made associations between bacterial lineage, or less frequently, genetic polymorphisms to in vitro or in vivo models of pathogenesis, transmission, and clinical outcomes such as cavitary disease, treatment failure, delayed culture conversion, and severity. Many of these studies focus on the global pandemic Lineage 2 and Lineage 4 Mtb strains due in part to a deletion in a polyketide synthase implicated in host-pathogen interactions. There are a number of Mtb GWAS studies that have led to novel genetic determinants of in vitro drug resistance and tolerance. Previous Mtb GWAS analyses with clinical outcomes did not experimentally test any predicted phenotypes of the clinical strains. Published laboratory-based studies of Mtb clinical strains involve relatively small numbers of strains, do not identify the genetic basis of relevant phenotypes, or link findings to the corresponding clinical outcomes. There are two recent studies of other pathogens that describe phenogenomic analyses. One study of 331 M. abscessus clinical strains performed one-by-one phenotyping to identify bacterial features associated with clearance of infection and another details a competition experiment utilizing three barcoded Plasmodium falciparum clinical isolates to assay antimalarial fitness and resistance. Added value of this study We developed a functional genomics platform to perform high-throughput phenotyping of Mtb clinical strains. We then used these phenotypes as intermediate traits to identify novel bacterial genetic features associated with clinical outcomes. We leveraged this platform with a sample of 158 Mtb clinical strains from a cross sectional study of Mtb transmission in Ho Chi Minh City, Vietnam. To enable high-throughput phenotyping of large numbers of Mtb clinical isolates, we applied a DNA barcoding approach that has not been previously utilized for the high-throughput analysis of Mtb clinical strains. This approach allowed us to perform pooled competitive fitness assays, tracking strain fitness using deep sequencing. We measured the replicative fitness of the clinical strains in multiplicate under 14 metabolic and antibiotic stress condition. To our knowledge, this is the largest phenotypic screen of Mtb clinical isolates to date. We performed bacterial GWAS to delineate the Mtb genetic variants associated with each fitness phenotype, identifying monogenic associations with several conditions. We then defined Mtb phenotypic and genetic features associated with clinical outcomes. We find that a s
BibTeX
@misc{stanley2023high,
author = {Sydney Stanley and Caitlin N. Spaulding and Qingyun Liu and Michael R. Chase and Đặng Thị Minh Hà and Phan Vuong Khac Thai and Nguyễn Hữu Lân and Do Dang Anh Thu and Nguyen Le Quang and Jessica Brown and Nathan Hicks and Xin Wang and Maximillian G. Marin and Nicole C. Howard and Andrew J. Vickers and Wiktor M. Karpinski and Michael C. Chao and Maha Farhat and Maxine Caws and Sarah J. Dunstan and Nguyễn Thụy Thương Thương and Sarah M. Fortune},
title = {{High-throughput phenogenotyping <i>of Mycobacteria tuberculosis</i> clinical strains reveals bacterial determinants of treatment outcomes}},
year = {2023},
doi = {10.1101/2023.04.09.536166},
howpublished = {bioRxiv},
}